scholarly journals Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension

2016 ◽  
pp. 1675
Author(s):  
Carlos Davila ◽  
Thomas Monaco
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Clinical Utility ◽  
Pulmonary Arterial

scholarly journals Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review

Core Evidence ◽  
2014 ◽  
pp. 71 ◽  
Author(s):  
Mitchell Buckley ◽  
Andrew Berry ◽  
Nadine Kazem ◽  
Shardool Patel ◽  
Paul Librodo
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Clinical Utility ◽  
Evidence Based ◽  
Pulmonary Arterial

scholarly journals Cortisol/cortisone levels and quality of life in individuals with pulmonary arterial hypertension

2020 ◽  
Vol 10 (2) ◽  
pp. 204589402092432
Author(s):  
RMR Tulloh ◽  
FF Quek ◽  
K Stevenson ◽  
V Garratt ◽  
JM Turner-Cobb
Keyword(s):  
Quality Of Life ◽  
Psychological Distress ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Salivary Cortisol ◽  
Clinical Utility ◽  
Potential Clinical Utility ◽  
Pulmonary Arterial

Individuals with pulmonary arterial hypertension experience debilitating symptoms and psychological distress which may influence their cortisol regulation. We describe associations between diurnal salivary cortisol/cortisone levels and quality of life in adults with pulmonary arterial hypertension. Findings suggest potential clinical utility of cortisol/cortisone assessment as applied to a pulmonary arterial hypertension population.

The effect of atrial septostomy on the concentration of brain-type natriuretic peptide in patients with idiopathic pulmonary arterial hypertension

2007 ◽  
Vol 17 (5) ◽  
pp. 557-559 ◽  
Author(s):  
Michael L O’Byrne ◽  
Erika S Berman Rosenzweig ◽  
Robyn J Barst
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Natriuretic Peptide ◽  
Cardiac Failure ◽  
Clinical Utility ◽  
Clinical Symptoms ◽  
Idiopathic Pulmonary Arterial Hypertension ◽  
Atrial Septostomy ◽  
Pulmonary Arterial ◽  
Serial Measurements

AbstractAtrial septostomy has improved haemodynamics and clinical symptoms in selected patients with idiopathic pulmonary arterial hypertension. We found that, in 5 patients with idiopathic pulmonary arterial hypertension, septostomy resulted in decreased levels of brain-type natriuretic peptide, and improvement in symptoms of cardiac failure, suggesting that serial measurements of the peptide may have clinical utility.

scholarly journals Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension

2012 ◽  
Vol 6 ◽  
pp. CCRPM.S8678 ◽  
Author(s):  
Shireen Mirza ◽  
Raymond J. Foley
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Clinical Utility ◽  
Congenital Heart ◽  
Vascular Wall ◽  
Pulmonary Vascular Disease ◽  
Immunodeficiency Virus ◽  
Pulmonary Arterial ◽  
Phosphodiesterase 5 ◽  
Substantial Morbidity

Pulmonary arterial hypertension (PAH) is a disease that leads to characteristic vascular wall remodeling and hemodynamic alterations. Consequently, this pulmonary vascular disease contributes to substantial morbidity and mortality in afflicted patients. PAH may be idiopathic in nature or associated with connective tissue disease, chronic liver disease, human immunodeficiency virus, congenital heart disease, and a growing list of other conditions. There are currently nine Food and Drug Administration-approved therapies for specific PAH treatment. Therapeutic targets include prostacyclin replacement, endothelin-1 antagonism, and phosphodiesterase-5 inhibition. This article focuses on the prostanoid treprostinil and explores its role in the management of patients with PAH.

Sign in / Sign up

Export Citation Format

Share Document